ArticleJournal of the American Pharmacists Association : JAPhA
Ready or not, here it comes: Direct-to-consumer pharmacogenomic testing and its implications for community pharmacists.
Article in Journal of the American Pharmacists Association : JAPhA. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy.The pharmacogenomics journal · 2026Article
- Knowledge, perceptions, and attitudes toward pharmacogenomics among pharmacists and pharmacy students: A systematic review.Health science reports · 2024Article
- Article
- The Critical Role of Pharmacists in the Clinical Delivery of Pharmacogenetics in the U.S.Pharmacy (Basel, Switzerland) · 2023Review
- An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers.Clinical pharmacology and therapeutics · 2023Article
- Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.Annual review of genomics and human genetics · 2022Review
- Pharmacists Leading the Way to Precision Medicine: Updates to the Core Pharmacist Competencies in Genomics.American journal of pharmaceutical education · 2022Article
- Nation-Wide Survey Assessing the Knowledge and Attitudes of Romanian Pharmacists Concerning Pharmacogenetics.Frontiers in pharmacology · 2022Article
- Documenting Pharmacogenomic Test Results in Electronic Health Records: Practical Considerations for Primary Care Teams.Journal of personalized medicine · 2021Article
- Engaging pharmacogenomics in pain management and opioid selection.Pharmacogenomics · 2021Review
- Independent Community Pharmacists' Experience in Offering Pharmacogenetic Testing.Pharmacogenomics and personalized medicine · 2021Article
- Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-Pharmacogenomics and personalized medicine · 2021Review
- Assessing the knowledge, perceptions, and practices of primary care clinicians toward pharmacogenetics.Journal of the American College of Clinical Pharmacy : JACCP · 2021Article
- Advanced Pharmacy Practice Experiences in Pharmacogenomics Offered by US Pharmacy Programs.American journal of pharmaceutical education · 2020Observational
- Barriers, solutions, and effect of using pharmacogenomics data to support opioid prescribing.Journal of managed care & specialty pharmacy · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
objectiveTo explore the implications of direct-to-consumer pharmacogenomic testing for community pharmacy practice. SUMMARY: In October 2018, the U.S. Food and Drug Administration provided approval for direct-to-consumer genetic testing company, 23andMe (Mountain View, CA), to return select pharmacogenomic test results to their customers. Given the community pharmacist's high accessibility to the public and in-depth knowledge of pharmacology, and the availability of direct-to-consumer genetic testing kits at pharmacies, it is likely that patients will present their pharmacogenomic test results to their pharmacists and expect them to incorporate those results into their care. It is important, therefore, that community pharmacists are aware of the clinical implications of these results, know where to turn for evidence-based clinical pharmacogenomics information, and be mindful of the need for confirmatory testing before changing therapy.
conclusionCommunity pharmacists are at the frontlines of health care, and as such will be at the frontlines of direct-to-consumer pharmacogenomic testing. In the near future, it is likely that community pharmacists will need to counsel patients on the interpretation and appropriate use of direct-to-consumer pharmacogenomic test results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.